These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
290 related articles for article (PubMed ID: 38753462)
1. The lethal K18-hACE2 knock-in mouse model mimicking the severe pneumonia of COVID-19 is practicable for antiviral development. Zhang Z; Zhou L; Liu Q; Zheng Y; Tan X; Huang Z; Guo M; Wang X; Chen X; Liang S; Li W; Song K; Yan K; Li J; Li Q; Zhang Y; Yang S; Cai Z; Dai M; Xian Q; Shi ZL; Xu K; Lan K; Chen Y Emerg Microbes Infect; 2024 Dec; 13(1):2353302. PubMed ID: 38753462 [TBL] [Abstract][Full Text] [Related]
2. SARS-CoV-2 Causes Lung Infection without Severe Disease in Human ACE2 Knock-In Mice. Winkler ES; Chen RE; Alam F; Yildiz S; Case JB; Uccellini MB; Holtzman MJ; Garcia-Sastre A; Schotsaert M; Diamond MS J Virol; 2022 Jan; 96(1):e0151121. PubMed ID: 34668780 [TBL] [Abstract][Full Text] [Related]
3. The K18-Human ACE2 Transgenic Mouse Model Recapitulates Non-severe and Severe COVID-19 in Response to an Infectious Dose of the SARS-CoV-2 Virus. Dong W; Mead H; Tian L; Park JG; Garcia JI; Jaramillo S; Barr T; Kollath DS; Coyne VK; Stone NE; Jones A; Zhang J; Li A; Wang LS; Milanes-Yearsley M; Torrelles JB; Martinez-Sobrido L; Keim PS; Barker BM; Caligiuri MA; Yu J J Virol; 2022 Jan; 96(1):e0096421. PubMed ID: 34668775 [TBL] [Abstract][Full Text] [Related]
4. Establishment and characterization of an h Liu H; Brostoff T; Ramirez A; Wong T; Rowland DJ; Heffner M; Flores A; Willis B; Evans JJ; Lanoue L; Lloyd KCK; Coffey LL Front Immunol; 2024; 15():1428711. PubMed ID: 39050847 [TBL] [Abstract][Full Text] [Related]
5. Ronapreve (REGN-CoV; casirivimab and imdevimab) reduces the viral burden and alters the pulmonary response to the SARS-CoV-2 Delta variant (B.1.617.2) in K18-hACE2 mice using an experimental design reflective of a treatment use case. Tatham L; Kipar A; Sharp J; Kijak E; Herriott J; Neary M; Box H; Gallardo Toledo E; Valentijn A; Cox H; Pertinez H; Curley P; Arshad U; Rajoli RKR; Rannard S; Stewart JP; Owen A Microbiol Spectr; 2024 Aug; 12(8):e0391623. PubMed ID: 39012120 [TBL] [Abstract][Full Text] [Related]
6. Human convalescent plasma protects K18-hACE2 mice against severe respiratory disease. Golden JW; Zeng X; Cline CR; Garrison AR; White LE; Fitzpatrick CJ; Kwilas SA; Bowling PA; Fiallos JO; Moore JL; Sifford WB; Ricks KM; Mucker EM; Smith JM; Hooper JW J Gen Virol; 2021 May; 102(5):. PubMed ID: 33961540 [TBL] [Abstract][Full Text] [Related]
7. Influence of Th1 versus Th2 immune bias on viral, pathological, and immunological dynamics in SARS-CoV-2 variant-infected human ACE2 knock-in mice. Verma SK; Ana-Sosa-Batiz F; Timis J; Shafee N; Maule E; Pinto PBA; Conner C; Valentine KM; Cowley DO; Miller R; Elong Ngono A; Tran L; Varghese K; Dos Santos Alves RP; Hastie KM; Saphire EO; Webb DR; Jarnagin K; Kim K; Shresta S EBioMedicine; 2024 Oct; 108():105361. PubMed ID: 39353281 [TBL] [Abstract][Full Text] [Related]
8. SARS-CoV-2 strains bearing Omicron BA.1 spike replicate in C57BL/6 mice. Ogger PP; Martín MG; Jang S; Zhou J; Brown J; Sukhova K; Furnon W; Patel AH; Cowton V; Palmarini M; Barclay WS; Johansson C Front Immunol; 2024; 15():1383612. PubMed ID: 38742107 [TBL] [Abstract][Full Text] [Related]
9. Characterization of the SARS-CoV-2 BA.5.5 and BQ.1.1 Omicron variants in mice and hamsters. Case JB; Scheaffer SM; Darling TL; Bricker TL; Adams LJ; Harastani HH; Trende R; Sanapala S; Fremont DH; Boon ACM; Diamond MS J Virol; 2023 Sep; 97(9):e0062823. PubMed ID: 37676002 [TBL] [Abstract][Full Text] [Related]
10. Mouse models of lung-specific SARS-CoV-2 infection with moderate pathological traits. Kim SH; Kim J; Jang JY; Noh H; Park J; Jeong H; Jeon D; Uhm C; Oh H; Cho K; Jeon Y; On D; Yoon S; Lim SY; Kim SP; Lee YW; Jang HJ; Park IH; Oh J; Seo JS; Kim JJ; Seok SH; Lee YJ; Hong SM; An SH; Kim SY; Kim YB; Hwang JY; Lee HJ; Kim HB; Choi KS; Park JW; Seo JY; Yun JW; Shin JS; Lee HY; Kim K; Lee D; Lee H; Nam KT; Seong JK Front Immunol; 2022; 13():1055811. PubMed ID: 36457995 [TBL] [Abstract][Full Text] [Related]
11. Efficacy of GC-376 against SARS-CoV-2 virus infection in the K18 hACE2 transgenic mouse model. Cáceres CJ; Cardenas-Garcia S; Carnaccini S; Seibert B; Rajao DS; Wang J; Perez DR Sci Rep; 2021 May; 11(1):9609. PubMed ID: 33953295 [TBL] [Abstract][Full Text] [Related]
12. Infectious Clones Produce SARS-CoV-2 That Causes Severe Pulmonary Disease in Infected K18-Human ACE2 Mice. Liu X; Zaid A; Freitas JR; McMillan NA; Mahalingam S; Taylor A mBio; 2021 Apr; 12(2):. PubMed ID: 33879586 [TBL] [Abstract][Full Text] [Related]
13. Characterization of Three Variants of SARS-CoV-2 In Vivo Shows Host-Dependent Pathogenicity in Hamsters, While Not in K18-hACE2 Mice. Toomer G; Burns W; Garcia L; Henry G; Biancofiori A; George A; Duffy C; Chu J; Sides M; Muñoz M; Garcia K; Nikolai-Yogerst A; Peng X; Westfall L; Baker R Viruses; 2022 Nov; 14(11):. PubMed ID: 36423193 [TBL] [Abstract][Full Text] [Related]
17. Hamsters Expressing Human Angiotensin-Converting Enzyme 2 Develop Severe Disease following Exposure to SARS-CoV-2. Golden JW; Li R; Cline CR; Zeng X; Mucker EM; Fuentes-Lao AJ; Spik KW; Williams JA; Twenhafel N; Davis N; Moore JL; Stevens S; Blue E; Garrison AR; Larson DD; Stewart R; Kunzler M; Liu Y; Wang Z; Hooper JW mBio; 2022 Feb; 13(1):e0290621. PubMed ID: 35073750 [TBL] [Abstract][Full Text] [Related]
18. Differential Outcomes of Infection by Wild-Type SARS-CoV-2 and the B.1.617.2 and B.1.1.529 Variants of Concern in K18-hACE2 Transgenic Mice. He Y; Henley J; Sell P; Comai L Viruses; 2023 Dec; 16(1):. PubMed ID: 38257760 [TBL] [Abstract][Full Text] [Related]
19. Development of transgenic models susceptible and resistant to SARS-CoV-2 infection in FVB background mice. Seo SM; Son JH; Lee JH; Kim NW; Yoo ES; Kang AR; Jang JY; On DI; Noh HA; Yun JW; Park JW; Choi KS; Lee HY; Shin JS; Seo JY; Nam KT; Lee H; Seong JK; Choi YK PLoS One; 2022; 17(7):e0272019. PubMed ID: 35881617 [TBL] [Abstract][Full Text] [Related]